Insulin resistance develops when your cells gradually stop responding to insulin’s signal to absorb sugar from your blood. Roughly 1 in 4 adults worldwide have it, with global estimates around 26 to 30 percent of the adult population. It doesn’t happen overnight or through a single broken mechanism. Instead, several overlapping processes in your fat tissue, liver, muscles, and even your gut converge to blunt insulin’s effects, often years before blood sugar levels rise enough to flag a problem.
What Insulin Normally Does Inside Your Cells
When you eat, your pancreas releases insulin into the bloodstream. Insulin molecules dock onto receptors on the surface of your cells, like a key fitting into a lock. That docking triggers a chain reaction inside the cell. The receptor activates a relay protein, which activates another, and so on down the line. The end result: glucose transporters (called GLUT4) travel from deep inside the cell to the outer membrane, where they act as gates that let sugar flow in from the blood.
This whole chain has two branches. One handles metabolism, moving sugar and nutrients into cells. The other promotes cell growth. The metabolic branch is more sensitive, meaning it kicks in at lower insulin levels. That detail matters because when resistance develops, the metabolic branch tends to fail first while the growth-promoting branch can keep going, creating an imbalance that drives some of insulin resistance’s downstream problems.
Fat Tissue Overflows and Spills Lipids
One of insulin’s most important jobs in fat tissue is suppressing the breakdown of stored fat. When insulin is working properly, it keeps fatty acids locked inside your fat cells between meals. In insulin resistance, this brake fails. Fat cells release a steady stream of free fatty acids into the bloodstream, and that flood reaches organs that aren’t designed to store much fat.
Excess lipids accumulate in the liver, skeletal muscle, the pancreas, and even the heart. This is called ectopic fat deposition, and it’s a central driver of the problem. The condition often starts with chronically high calorie intake combined with fat tissue that can no longer expand or function properly. Inflammatory signals from overstuffed fat cells compound the problem by disrupting insulin signaling in distant organs like the liver and muscles, creating a cycle where inflamed fat tissue makes other tissues resistant too.
Some populations are more vulnerable to this overflow. South Asian individuals, for example, tend to have lower capacity for storing fat safely under the skin, which means excess calories get rerouted to visceral fat and organs at lower overall body weights.
What Happens in the Liver
The liver illustrates a strange feature of insulin resistance called selective resistance. Normally, insulin tells the liver to do two things: stop producing glucose and start converting excess carbohydrates into fat. In insulin resistance, the liver loses its ability to stop making glucose (contributing to high blood sugar), but it retains and even ramps up its fat-making capacity. The pancreas responds to rising blood sugar by pumping out more insulin, and that extra insulin drives even more liver fat production. The result is a fatty liver that simultaneously overproduces both sugar and triglycerides.
The biochemistry behind this involves how the liver handles incoming fatty acids. In the fed state, a molecule called malonyl CoA rises and blocks fatty acids from entering the mitochondria (the cell’s energy furnaces) for burning. Instead, those fatty acids get repackaged into triglycerides. When insulin resistance floods the liver with free fatty acids from leaky fat tissue, and high insulin levels keep malonyl CoA elevated, fat accumulates rapidly. This is the pathway that leads to fatty liver disease, a condition now affecting a substantial portion of people with insulin resistance.
Inflammation Jams the Insulin Signal
Overstuffed fat cells don’t just leak fatty acids. They also release inflammatory molecules, including TNF-alpha, IL-6, and IL-1 beta. These cytokines activate two stress-sensing enzymes inside cells called JNK and IKK-beta. Both enzymes interfere with the relay protein that sits near the top of insulin’s signaling chain.
Here’s the specific sabotage: the relay protein needs to be tagged at certain spots to pass the insulin signal forward. JNK tags it at the wrong spots, which shuts down the signal instead of transmitting it. Meanwhile, IKK-beta activates a master inflammatory switch called NF-kB, which turns on genes that produce even more inflammatory molecules. This creates a feed-forward loop: inflammation causes resistance, resistance worsens fat overflow, fat overflow increases inflammation.
Mitochondrial Stress Blocks Sugar Uptake
Your cells burn fuel inside mitochondria, and when those mitochondria are under stress, they produce excess reactive oxygen species, essentially corrosive byproducts of metabolism. Research published in the Journal of Biological Chemistry showed that increasing these mitochondrial oxidants alone is enough to cause insulin resistance, even when the mitochondria are otherwise functioning normally.
What’s striking is how targeted this damage is. Mitochondrial oxidative stress specifically prevents GLUT4 transporters from reaching the cell surface, so sugar can’t get in. It does this without disrupting the earlier steps in insulin’s signaling chain. The signal from the insulin receptor travels partway down the relay normally, but the final step of moving the glucose gates into position fails. This selectivity explains why some people can have near-normal insulin signaling markers on a blood test while still having measurably impaired glucose uptake in their muscles.
Your Gut Bacteria Add Fuel
The gut lining normally acts as a tight barrier, keeping bacteria and their byproducts contained. That barrier is maintained by specialized junction proteins that seal the gaps between intestinal cells. In people with insulin resistance, expression of these junction proteins drops, and the barrier becomes leaky. Fragments of bacterial cell walls, called lipopolysaccharides (LPS), slip into the bloodstream.
Even small amounts of circulating LPS trigger a significant immune response. LPS activates a receptor on immune cells called TLR4, which sets off the same JNK and IKK-beta pathways that inflammatory cytokines activate. The result is the same: the insulin relay protein gets tagged at the wrong sites, and insulin signaling stalls. LPS also increases production of nitric oxide in a way that chemically modifies the insulin receptor itself, further impairing its function. This gut-driven inflammation helps explain why insulin resistance is a whole-body condition rather than a problem in one organ.
High Insulin Itself Makes Resistance Worse
Perhaps the most vicious cycle in insulin resistance is that the body’s own compensatory response accelerates the problem. When cells stop responding to insulin, the pancreas produces more of it to compensate. Chronically elevated insulin then causes cells to physically reduce the number of insulin receptors on their surfaces.
This isn’t just receptor fatigue. Research on muscle cells has shown that sustained high insulin reduces receptor numbers in a dose-dependent manner: the higher the insulin, the fewer receptors remain. The mechanism works at the genetic level. High insulin activates a signaling molecule that locks a key transcription factor (FOXO1) out of the cell nucleus. Since FOXO1 is responsible for telling the cell to make more insulin receptors, silencing it means fewer receptors get produced. At the same time, high insulin increases a transcriptional repressor called SIN3A that actively suppresses receptor production. The cell is simultaneously losing its “make more receptors” signal and gaining a “stop making receptors” signal.
This means the compensatory hyperinsulinemia that keeps blood sugar in check for years is quietly deepening the underlying resistance the entire time.
How Insulin Resistance Is Measured
The most common clinical tool is HOMA-IR, calculated from a fasting blood sugar and fasting insulin level. There’s no single universal cutoff, but a score of 2.5 or above is widely used in U.S. research to indicate insulin resistance. For context, normal-weight U.S. adolescents average about 2.3, while adolescents with obesity average 4.9. In Asian populations, the thresholds tend to be lower, typically between 1.4 and 2.5, reflecting differences in body composition and metabolic risk at lower body weights.
HOMA-IR is useful as a snapshot, but it captures a late stage. Many of the processes described above, including ectopic fat deposition, low-grade inflammation, and receptor downregulation, are well underway before the score crosses a diagnostic threshold. Waist circumference, triglyceride-to-HDL ratio, and fasting insulin levels on their own can all provide earlier clues that resistance is developing.